Novartis, the Swiss pharmaceutical company, on Monday said it had delayed approval by US regulators of Galvus, its new potential blockbuster diabetes drug Galvus by three months to allow submission of additional clinical data.
» Search Healthcare-Specific Tags: Novartis - Galvus